在一项比较研究中,人格特征解释了迷幻药使用与较少抑郁症之间的关系
David K Sjöström1, Emma Claesdotter-Knutsson1,2, Petri J Kajonius3
1Child and Adolescent Psychiatry, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.
Scientific reports
|May 3, 2024
概括
与非使用者相比,迷幻药物的使用者报告说抑郁症较低,吸毒率更高. 人格特征,特别是开放性和较低的神经性,部分解释了迷幻消费者的心理健康差异.
科学领域:
- 心理药理学和心理健康研究.
- 调查迷幻药物对心理健康的影响.
背景情况:
- 越来越多的兴趣在心理学为心理健康的好处.
- 人们仍然担心潜在的不良心理影响.
- 人格特征可能会影响迷幻体验和结果.
研究的目的:
- 为了比较瑞典迷幻药使用者和非使用者之间的心理健康和人格特征.
- 探索迷幻药使用者的个性和心理健康之间的关系.
主要方法:
- 一项针对400名瑞典迷幻药使用者和400名匹配对照者的全国性在线调查.
- 评估心理健康变量:抑郁症 (PHQ-9),失眠,问题性酒精和毒品使用 (DUDIT) 和分离.
- 使用大五大库存对人格的评估.
主要成果:
- 迷幻药物使用者报告说,抑郁症显著减少 (PHQ-9) 和药物使用率更高 (DUDIT).
- 在迷幻药使用者中,开放性是一个明显更高的特征.
- 用户中神经病症得分较低部分解释了抑郁症水平的降低.
结论:
- 迷幻药使用者表现出明显的心理健康状况,其特点是抑郁症较少,吸毒率较高.
- 人格特征,特别是较低的神经性和更高的开放性,与这些差异有关.
- 研究结果表明,迷幻药的使用,个性和心理健康结果之间存在复杂的相互作用.
相关概念视频
Hallucinogens and Psychedelics
164
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
164
The Placebo Effect
6.1K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.1K
Depressive Disorders: Etiology
71
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
71
Antidepressant Drugs: MAOIs and Other Agents
227
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
227
CNS Stimulants: Psychedelic Agents
147
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
147
Electroconvulsive Therapy
37
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
37


